Philadelphia Launches Women's Health Innovation Program
The new program helps 10 startups develop medical technology designed to improve diagnostic accuracy for women.
Updated on Oct. 15, 2026 in Women’s Health
Live Poll
Should healthcare startups be required to tailor their medical products for both female and male biology?
Philadelphia-based nonprofit Upstart Impacts has launched a new innovation program designed to help early-stage medtech startups address gaps in women's healthcare. Ten companies will be selected for the cohort to receive mentorship and funding support starting in February 2027.
Why it matters
The program aims to address systemic medical inequities, such as the fact that women are twice as likely to experience adverse drug effects and 50% more likely to be misdiagnosed after a heart attack. Currently, women's health research receives only about 5% of global healthcare R&D funding.
A 2025 pilot program supported 10 companies that collectively raised $7.4 million to advance their technologies. Despite this, it remains unknown how these specific startups will impact broader clinical outcomes, given that women's health currently captures only 5% of global healthcare R&D funding.
The players
Upstart Impacts
A Philadelphia-based nonprofit organization that provides mentorship and resources for early-stage life sciences and medtech startups.
The details
The program works by providing participants with mentorship, access to experts, and connections to funding sources, all without requiring equity. By focusing on integrating female biology into the development phase, the initiative attempts to correct historical biases in medical research. This structure helps bridge the gap between early-stage innovation and the resources required to bring health technologies to market.
Timeline
October 15, 2026: The application window opened for the new program.
December 15, 2026: The deadline for companies to submit their applications.
January 2027: The organization will announce the 10 selected startups.
February 2027: The innovation program officially begins.
Health Landscape
This initiative represents a localized effort to shift the current medical landscape, where women's health research remains significantly underfunded. By prioritizing female biology in early-stage development, the program attempts to address the systemic imbalances that contribute to persistent diagnostic and safety gaps for women.
While this program focuses on the development phase of medical technology, its ultimate goal is to reduce the risk of misdiagnosis and adverse drug reactions for women. If you are concerned about how diagnostic tools or treatments account for biological differences, these are important topics to discuss with your physician.
The takeaway
Advancing medical technology that explicitly accounts for female biology is a critical step toward safer, more accurate healthcare for women. Patients should keep an eye on how new screening tools and medications are validated for their specific physiological needs during conversations with their doctor.
Further reading
For more on the efforts to improve patient care, see our coverage of Women’s Health.
More information
To apply for the upcoming cohort, visit the women's health innovation program application.
Live Poll
Should healthcare startups be required to tailor their medical products for both female and male biology?
